Year: 2023

Cullgen_logo_FINAL_4-21-2020_transparent_PNG

Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients

CG001419 is Cullgen’s first protein degrader to enter clinical development SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen Inc., a leading biotechnology company...

Stronghold-Digital-Mining-Inc-1-1

Stronghold Digital Mining Purchases 2,000 New A1346 Bitcoin Miners From Canaan Inc. and the Companies Expand Their Existing Bitcoin Mining Agreement with an Additional 2,000 A1346 Miners